Clinical trial
Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast…
NCT00004935 · Swiss Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00004935 |
|---|---|
| Title | Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2 |
| Official title | Randomized Phase III Trial of Herceptin® Followed by Chemotherapy Plus Herceptin® Versus the Combination of Herceptin® and Chemotherapy as Palliative Treatment in Patients With HER2- Overexpressing Advanced/Metastatic Breast Cancer. |
| Lead sponsor | Swiss Cancer Institute, Other |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Herceptin™ (Her), Herceptin™ (Her) + chemo |
| Enrollment | 175 |
| Start date | Aug 30, 1999 |
| Primary completion | Nov 6, 2014 |
| Completion | Mar 31, 2022 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 18, 2023 |
| Countries | Italy, Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: